Raymond James Financial Services Advisors Inc. raised its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 18.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,787 shares of the company’s stock after purchasing an additional 1,673 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Crispr Therapeutics were worth $657,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in shares of Crispr Therapeutics in the 4th quarter valued at $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics during the 4th quarter worth $26,000. Advisory Services Network LLC raised its position in Crispr Therapeutics by 146.0% during the 4th quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock worth $41,000 after purchasing an additional 400 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in Crispr Therapeutics during the 4th quarter worth $44,000. Finally, Exchange Traded Concepts LLC bought a new position in Crispr Therapeutics during the 4th quarter worth $54,000. Institutional investors own 52.02% of the company’s stock.
Shares of CRSP traded down $1.31 during trading hours on Friday, hitting $42.68. The stock had a trading volume of 343,495 shares, compared to its average volume of 1,081,499. The firm has a 50 day simple moving average of $48.95 and a 200-day simple moving average of $52.92. The firm has a market capitalization of $2.54 billion, a P/E ratio of 44.00 and a beta of 2.74. Crispr Therapeutics AG has a 1-year low of $32.30 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. The company had revenue of $77.00 million during the quarter, compared to the consensus estimate of $39.08 million. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The firm’s revenue for the quarter was up 76900.0% compared to the same quarter last year. During the same period last year, the business posted ($0.92) EPS. On average, research analysts forecast that Crispr Therapeutics AG will post -4.54 EPS for the current fiscal year.
Several research analysts recently issued reports on CRSP shares. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Piper Sandler reaffirmed a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research report on Thursday, February 13th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Stifel Nicolaus started coverage on Crispr Therapeutics in a research report on Wednesday, March 4th. They set a “hold” rating and a $52.00 target price for the company. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the stock. Crispr Therapeutics currently has a consensus rating of “Buy” and an average target price of $72.25.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is Cost of Debt?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.